Anteris Technologies reveals trials data of its aortic valve replacement
Brisbane medtech manufacturer Anteris Technologies has announced positive 12-month results from the first-in Human (FIH) study designed to evaluate the safety and efficacy of its DurAVR aortic valve replacement device (pictured) in patients with symptomatic severe aortic stenosis. DurAVR is a new class of aortic valve that utilises the company’s patented ADAPT anti-calcification process and…